The use of bacillus PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
An intestinal disease, Bacillus technology, applied in the direction of using bacteria, medical raw materials derived from bacteria, medical preparations that are not active ingredients, etc.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0036] Example 1: Efficacy of Bacillus PB6 against Clostridium difficile AAD and CDAD
[0037] The antagonism of Bacillus PB6 against Clostridium perfringens ATCC13124 and Clostridium difficile ATCC9689 was tested.
[0038] Bacillus PB6 has antagonistic effects on Clostridium perfringens ATCC 13124 and Clostridium difficile ATCC9689. A clear ring was observed at the intersection of the dashed lines on the plates of the two strains. An example of the assay plate is at figure 1 shown in .
[0039] Bacillus PB6 has antagonistic effect on Clostridium difficile N API / 027. This strain of C. difficile has been associated with several high-risk disease outbreaks and has shown resistance to antibiotics. An example of the assay plate is at figure 2 shown in .
[0040] To determine the antimicrobial effect of secondary metabolites of Bacillus sp. PB6, the bacteria were fermented and the fermentation products were extracted by diethyl ether. The organic layer was separated, concen...
Embodiment 2
[0152] Example 2: Determination of different probiotics and Bacillus amyloliquefaciens by broth microdilution Antimicrobial properties of PB6 metabolites against Clostridium perfringens and Clostridium difficile
[0153] In this study, we investigated the anti-clostridial properties of Bacillus sp. PB6 and metabolites of 4 commercially available probiotics: (Sanofi-synthelabo), (Biodiphar), Bioplus 2B (Miavit GmbH) and Biosporinum (Dniprofarm). Setting up small-scale fermentations using strains isolated from different probiotics. Ether extracts of fermentation broths containing the metabolites were screened against C. perfringens ATCC13124 and C. difficile ATCC9689 using broth microdilution. Metabolites of Bacillus PB6 showed significant anti-clostridial properties. The minimum inhibitory concentration is between 2.5 and 5.0 μg / ml (for C. perfringens) and between 5.0 and 10.0 μg / ml (for C. difficile). Ether extracts of Bioplus 2B and Biosporinum fermentation broths d...
Embodiment 3
[0168] Example 3: Efficacy of Bacillus PB6 against IBD
[0169] Surfactin is known to inhibit the activity of cytosolic PLA2, an enzyme primarily involved in many inflammatory processes 58 . Inhibition of inflammatory processes makes surfactin-producing probiotics of great interest for the treatment of inflammatory diseases such as inflammatory bowel disease (IBD).
[0170] Inflammatory bowel disease refers to two chronic diseases that cause intestinal inflammation: ulcerative colitis (UC) and Crohn's disease (CD). Although the diseases share some common features, they have some important differences.
[0171] CD is a chronic inflammation of the bowel wall that typically affects the entire thickness of the bowel wall. It most commonly occurs in the lowest part of the small intestine (ileum) and large intestine, but it can also occur in any part of the digestive tract from the mouth to the anus and the skin around the anus.
[0172] In the last decade, CD has become a mor...
PUM
Property | Measurement | Unit |
---|---|---|
concentration | aaaaa | aaaaa |
concentration | aaaaa | aaaaa |
concentration | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com